Company Filing History:
1 out of 44 
1 out of 223 
1 out of 489 
Years Active: 2006-2017
Title: Claude Libert: Innovator in Antigen Binding Proteins and Liver Protection
Introduction
Claude Libert is a notable inventor based in Oudenaarde, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins and liver protection mechanisms. With a total of 2 patents, his work has implications for treating various inflammatory conditions and liver diseases.
Latest Patents
One of Claude Libert's latest patents is focused on MMP8 inactivating antigen binding proteins. This patent describes antigen binding proteins that comprise an amino acid sequence with four framework regions and three complementary determining regions. The use of these proteins is aimed at treating inflammation, including conditions such as systemic inflammatory response syndrome, sepsis, and rheumatoid arthritis. Another significant patent is related to Abin-mediated hepatitis protection. This invention utilizes the A20-binding inhibitor of NF-κB activation (ABIN) to protect against TNF-induced liver failure, including viral hepatitis and alcoholic liver disease. The focus is on preventing the toxic effects of these diseases by overexpressing ABIN.
Career Highlights
Claude Libert has worked with prominent organizations, including the Flemish Interuniversity Institute for Biotechnology (VIB). His research has contributed to advancements in understanding and treating complex diseases.
Collaborations
Throughout his career, Claude Libert has collaborated with esteemed colleagues such as Rudi Beyaert and Ben Wielockx. These partnerships have fostered innovation and enhanced the impact of his research.
Conclusion
Claude Libert's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and therapies.